Since the MOC2 oral cancer model showed that Sema6d-KO mice exhibited greater CD8+ T cell infiltration in the TME than WT mice, we treated both groups of mice with a PD-1–blocking antibody (Figure 7A). Here, SEMA6D is linked to lip and oral cavity carcinoma.